Scilex (SCLX) said Wednesday it has concluded its phase 2 meeting with the US Food and Drug Administration regarding its product candidate SP-103, which is intended for treating neck pain with muscle spasms.

The FDA outlined a clear pathway to a new drug application following the completion of phase 3 trials, the company said.

Shares of Scilex were up 1.5% in recent Wednesday trading.

Price: 1.01, Change: +0.02, Percent Change: +1.51